Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Nationwide, Cohort study to evaluate the Risks associated with the treatment of Rituximab, Fingolimod and Natalizumab in Swedish patients with Multiple Sclerosis

Trial Profile

A Nationwide, Cohort study to evaluate the Risks associated with the treatment of Rituximab, Fingolimod and Natalizumab in Swedish patients with Multiple Sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary) ; Natalizumab (Primary) ; Rituximab (Primary) ; Glatiramer acetate; Interferon beta
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Oct 2019 Results examining the risk of serious infections associated with disease-modifying treatments for multiple sclerosis published in the JAMA Neurology
    • 30 Oct 2018 New trial record
    • 12 Oct 2018 Results assessing the risk of infections in multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top